ReAlta Life Sciences, Inc. (“ReAlta”) a clinical stage, rare disease company addressing life-threatening diseases through harnessing the power of the...
Read MoreNorfolk, VA, April 5, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive...
Read MoreNorfolk, VA, February 22, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer is scheduled...
Read MoreThe review article, “The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action and In Vivo and...
Read MoreNorfolk, VA, January 6th, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer is...
Read MoreMyeloperoxidase activity in individuals with Anti-neutrophil cytoplasmic antibodies (ANCA) can be inhibited by RLS-0071 At the 2021 Annual Conference of...
Read MoreNorfolk, VA, November 2, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer, will...
Read MoreNorfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and...
Read MoreNorfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and John...
Read More